Book chapter
Chapter 14 - No Mechanism is an Island: Interactions Among Monoclonal Antibody Mechanisms of Action
Antibody Fc: Linking Adaptive and Innate Immunity, pp.257-267
Elsevier Inc
2014
DOI: 10.1016/B978-0-12-394802-1.00014-5
Abstract
Monoclonal antibodies (mAbs), including rituximab, are now a mainstay in the therapy of cancer. Despite their undeniable therapeutic value, there is much we do not fully understand about the mechanisms of action responsible for their anti-tumor effects. These mechanisms are often studied in isolation. In this chapter, we will review the mechanisms of action of anti-cancer mAbs and discuss how they interact. The focus of this discussion will be on rituximab, but similar conclusions can be reached with other mAbs.
Details
- Title: Subtitle
- Chapter 14 - No Mechanism is an Island: Interactions Among Monoclonal Antibody Mechanisms of Action
- Creators
- George J. Weiner - University of Iowa
- Resource Type
- Book chapter
- Publication Details
- Antibody Fc: Linking Adaptive and Innate Immunity, pp.257-267
- Publisher
- Elsevier Inc
- DOI
- 10.1016/B978-0-12-394802-1.00014-5
- Language
- English
- Date published
- 2014
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984359894802771
Metrics
11 Record Views